How to Use Risk-Based Monitoring and Clinical CAPA to Ensure Compliance
If your company is a sponsor or a CRO that conducts clinical research for a sponsor, how effective are your risk management and clinical CAPA processes? Are you...
Executive Abstract
This white paper will discuss the importance of risk-based monitoring and CAPA in clinical research within the context of the following initiatives by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA):
Unlock Report Access
Complete this brief form for instant PDF access.
Related Executive Research
White Paper
How To Choose An Immunoassay Platform For Cell & Gene Therapy Bioanalysis
The key factors to automating assay development to get results quicker Given the recent approval of an adeno-associated viral (AAV) vector gene therapy for spi...
Guide
Chronic Obstructive Pulmonary Disease- Pipeline Analysis 2018
There are total 141 molecules in pipeline (Company Molecules 90, University & Institute Molecules 51) in different phases of development. There are total 141 m...
White Paper
Increasing Patient Engagement and Helping Clinical Trials Reach Full Potential with the Clinical Research as a Care Option Model
Only 3% of people with cancer participate in clinical trials. CRAACO seamlessly integrates clinical research with medical care, so more patients and physicians...